3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Carcinoma, Renal Cell
4
Neoplasm Metastasis
3
Melanoma
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Metastatic Castration-resistant Prostate Cancer
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
33
Nivolumab
15
atezolizumab
9
Cyclophosphamide
7
Paclitaxel
6
Ipilimumab
6
spartalizumab
5
fludarabine
5
Docetaxel
5
durvalumab
4
avelumab
4
Immune Checkpoint Inhibitors
4
Carboplatin
4
olaparib
3
cemiplimab
3
cabozantinib
3
Specimen Handling
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Interleukin-2
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
sacituzumab govitecan
2
obinutuzumab
2
lenvatinib
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
bempegaldesleukin
×
Genitourinary
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts